ClinicaliQ Trial Snapshot
- Study for AZD4360 in Participants With Advanced Solid Tumours — Recruiting • Phase I • Oncology • NCT06921928.
- What is being tested: AZD4360, a novel therapeutic agent, is being evaluated for safety, tolerability, pharmacokinetics, immunogenicity, and preliminary efficacy in patients with advanced solid tumours expressing CLDN18.2, a tumour-associated antigen.
- Patient eligibility overview: The study includes adult patients with locally advanced or metastatic solid tumours that have been selected based on confirmed CLDN18.2 expression, restricting participation to patients whose tumours express this specific biomarker.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
The purpose of this study is to evaluate the safety, tolerability, PK, immunogenicity, pharmacodynamics, and preliminary efficacy of AZD4360 in adult participants with locally advanced or metastatic solid tumours selected for expression of CLDN18.2.
Eligibility Snapshot
- :
- Participant must be ≥ 18 at the time of signing the ICF. 2. Eastern cooperative oncology group performance status of 0-1 with no deterioration over the previous 2 weeks prior to baseline or day of first dosing. 3. Minimum life expectancy of 12 weeks in the opinion of the Investigator. 4 Adequate organ and marrow function, as defined by protocol. 5. Contraceptive use by men or women should be consistent with local regulations, as defined by protocol. 6. Histologically confirmed advanced or metastatic Pancreatic ductal adenocarcinoma (PDAC), Gastric or Gastroesophageal junction cancer (G/GEJC), and Biliary tract cancer (BTC) with documented positive CLDN18.2 expression.
- Participants must have received at least one prior line of systemic therapy in the advanced/metastatic disease. 8. At least one measurable lesion according to RECIST v1.1.
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.